Literature DB >> 6650979

The effects of chronic hyperinflation, nutritional status, and posture on respiratory muscle strength in cystic fibrosis.

S O'Neill, F Leahy, H Pasterkamp, A Tal.   

Abstract

We measured maximal static inspiratory and expiratory pressures (PImax and PEmax) in 25 patients with cystic fibrosis (CF) and 80 normal control subjects to determine whether chronic hyperinflation and malnutrition reduce PImax and PImax/PEmax, respectively. In addition, we examined the effect of posture on pressures generated. We used a diminution in PEmax as an index of a malnutrition effect on pressures generated. The patients with CF, although significantly hyperinflated (ratio of residual volume to total lung capacity, 0.49), generated PImax values similar to those of the control subjects (p greater than 0.05). Despite evidence of malnutrition (mean body mass percentile, 78%) the PEmax values of patients with CF and those of control subjects were comparable (p greater than 0.05). There was no postural effect on pressures generated in the normal subjects or the CF group as a whole. We conclude that respiratory muscle strength is normal or supranormal in CF, despite chronic hyperinflation and malnutrition.

Entities:  

Mesh:

Year:  1983        PMID: 6650979     DOI: 10.1164/arrd.1983.128.6.1051

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  4 in total

1.  Respiratory muscle function in cystic fibrosis.

Authors:  A Mier; A Redington; C Brophy; M Hodson; M Green
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

Review 2.  Exercise recommendations for individuals with cystic fibrosis.

Authors:  S R Boas
Journal:  Sports Med       Date:  1997-07       Impact factor: 11.136

Review 3.  Exercise and cystic fibrosis.

Authors:  A K Webb; M E Dodd; J Moorcroft
Journal:  J R Soc Med       Date:  1995       Impact factor: 5.344

Review 4.  A practical approach to oxygen therapy in cystic fibrosis.

Authors:  M E Dodd; C S Haworth; A K Webb
Journal:  J R Soc Med       Date:  1998       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.